SINOVAC BIOTECH LTD
SVANext catalyst
Experimental vaccine
Poliomyelitis
Get an email about SVA's next catalysts
Track SINOVAC BIOTECH (SVA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 2 more upcoming events in our data (Phase 3 readout).See the timeline
3 upcoming, 1 past
experimental vaccine Phase 3 Est. Readout
Estimated primary completion for experimental vaccine trial (NCT07505836) in Epidemic Meningitis. Topline data typically follows completion by weeks to months.
Sourceexperimental vaccine Phase 3 Est. Readout
Estimated primary completion for experimental vaccine trial (NCT07505810) in Epidemic Meningitis. Topline data typically follows completion by weeks to months.
SourceInactivated Hepatitis A Vaccine (Human Diploid Cell) Phase 3 Est. Readout
Estimated primary completion for Inactivated Hepatitis A Vaccine (Human Diploid Cell) trial (NCT07793227) in Hepatitis A Vaccine. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14 in elderly
Covid19
PROVARIX
Varicella (Chickenpox)
36-71 months old children-experimental EV71 vaccine
Hand, Foot and Mouth Disease
investigational 23-valent PPV
Pneumococcal Infections
Investigational sIPV
Poliomyelitis
EV71 vaccine
Hand, Foot and Mouth Disease
three consecutive lots of EV71 vaccine
Hand, Foot and Mouth Disease
Three doses of experimental sIPV of lot 1 at the schedule of 2,3,4 months of age
Poliomyelitis
Quadrivalent influenza vaccine
Seasonal Influenza
sIPV-sIPV-bOPV vaccination schedule
Poliomyelitis
Trivalent influenza vaccine (contains B/Victoria strain)
Seasonal Influenza
sIPV-bOPV-bOPV vaccination schedule
Poliomyelitis
Influenza Vaccine (Split Virion), Inactivated, Quadrivalent
Seasonal Influenza
Experimental vaccine
Poliomyelitis
bivalent enterovirus vaccine (Vero cell), inactivated
Hand, Foot, and Mouth Disease(HFMD)
Sabin Strain Inactivated Poliovirus Vaccine
Poliomyelitis
Participants will receive one dose of vaccine of Sinovac QIV
Influenza
Investigational tetanus vaccine, adsorbed
Tetanus
Two doses of commercial scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14
Covid19
Vaccine manufactured at commercialized scale
Varicella
Sinovac PCV13
Pneumococcal Infectious Disease
investigational live attenuated mumps vaccine
Mumps
control live attenuated mumps vaccine
Mumps
Inactivated COVID-19 Vaccine
COVID-19
Investigational live attenuated varicella vaccine
Varicella
COVID-19 Vaccine,Inactivated
COVID-19
Varicella Vaccine
Varicella
COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)
COVID-19
SARS-CoV-2 Inactivated Vaccine
COVID-19
Sinovac rabies vaccine
Rabies (Healthy Volunteers)
SARS-CoV-2 vaccine (inactivated)
SARS-CoV2 Infection
Inactivated Hepatitis A Vaccine (Human Diploid Cell)
Hepatitis A Vaccine
Trivalent influenza vaccine(BV)
Seasonal Influenza
Adsorbed COVID-19 (inactivated) Vaccine
COVID-19
Trivalent influenza vaccine(BY)
Seasonal Influenza
Three doses of experimental sIPV of lot 2 at the schedule of 2,3,4 months of age
Poliomyelitis
Three doses of experimental sIPV of lot 3 at the schedule of 2,3,4 months of age
Poliomyelitis
Two doses of pilot scale inactivated SARS-CoV-2 vaccine at the schedule of day 0,14
Covid19
Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
COVID-19
Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
COVID-19
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
COVID-19
Three doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
COVID-19
High-dose experimental vaccine
Herpes Zoster
Sinovac Low-dosage PCV24
Pneumococcal Infectious Disease
CoronaVac®
COVID-19
medium dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
Hand, Foot and Mouth Disease
Sinovac Middle-dosage PCV24
Pneumococcal Infectious Disease
Omicron Vaccine
COVID-19
Single-dose regimen of high dosage investigational sIPV
Poliomyelitis
Three doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
COVID-19
Tetanus Toxoid
Tetanus
pandemic influenza vaccine (H5N1 strain NIBRG-14)
Pandemic Influenza
EV71 vaccine with adjuvant
Infection, Viral, Enterovirus
SNA02-48
Tetanus
split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)
Influenza
Medium-dose tetravalent inactivated enterovirus vaccine (Vero cell)
Hand, Foot, and Mouth Disease (HFMD)
Sinovac High-dosage PCV24
Pneumococcal Infectious Disease
Three-dose regimen of high dosage investigational sIPV
Poliomyelitis
Three-dose regimen of low dosage investigational sIPV
Poliomyelitis
Low-dose experimental vaccine
Herpes Zoster
low dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
Hand, Foot and Mouth Disease
Low-dose of tetravalent inactivated enterovirus vaccine (Vero cell)
Hand, Foot, and Mouth Disease (HFMD)
high dose Bivalent Enterovirus Vaccine (Vero Cell), Inactivated
Hand, Foot and Mouth Disease
Trivalent Vaccine
COVID-19
COVID-19 Vaccine (Vero Cell), Inactivated, Omicron Strain
COVID-19
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
COVID-19
EV71 vaccine without adjuvant
Infection, Viral, Enterovirus
Two doses of low dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
COVID-19
Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
COVID-19
Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
COVID-19
Oral hexavalent reassortant rotavirus attenuated live vaccine
Rotavirus Gastroenteritis
Three doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
COVID-19
Sinovac PCV24
Pneumococcal Infectious Disease
Single-dose regimen of medium dosage investigational sIPV
Poliomyelitis
Three-dose regimen of medium dosage investigational sIPV
Poliomyelitis
High-dose tetravalent inactivated enterovirus vaccine (Vero cell))
Hand, Foot, and Mouth Disease (HFMD)
Two doses of high dosage inactivated SARS-CoV-2 vaccine at the schedule of day 0,28
COVID-19
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in SINOVAC BIOTECH LTD's drug pipeline?→
CatalystAlert tracks 77 drug candidates in SINOVAC BIOTECH LTD's (SVA) pipeline across Phase 3, Phase 2. Its lead program is Experimental vaccine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is SINOVAC BIOTECH LTD's next FDA catalyst?→
SINOVAC BIOTECH LTD's (SVA) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track SVA biotech catalysts?→
Add SVA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow SINOVAC BIOTECH LTD's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
